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BACKGROUND: High-dose opioid therapy can precipitate seizures; however, the
mechanism of such a dangerous adverse effect remains poorly understood. The aim
of our study was to determine whether the neuroexcitatory activity of high-dose
morphine is mediated by selective stimulation of opioid receptors.
METHODS: Mice hippocampi were resected intact and bathed in low magnesium
artificial cerebrospinal fluid to induce spontaneous seizure-like events recorded
from CA1 neurons.
RESULTS: Application of morphine had a biphasic effect on the recorded spontane-
ous seizure-like events. In a low concentration (10 M), morphine depressed
electrographic seizure activity. Higher morphine concentrations (30 and 100 M)
enhanced seizure activity in an apparent dose-dependent manner. Naloxone, a
nonselective opiate antagonist blocked the proconvulsant action of morphine.
Selective  and  opiate receptor agonists and antagonists enhanced and sup-
pressed the spontaneous seizure activity, respectively. On the contrary,  opioid
receptor ligands did not have an effect.
CONCLUSIONS: The proseizure effect of morphine is mediated through selective
stimulation of  and  opiate receptors but not the activation of the  receptor
system. The observed dose-dependent mechanism of morphine neuroexcitation
underscores careful adjustment and individualized opioid dosing in the clinical
setting.
(Anesth Analg 2007;105:1729–35)
Chronic severe pain afflicts more than 6% of the
general population, and high-dose opioids are the
mainstay of treatment (1). As research and education
regarding the importance of opioid use in chronic
severe pain continue to improve, the number of pa-
tients treated with high-dose opioids increases corre-
spondingly, as does the incidence of opioid-related
adverse effects (2). Among the most curious and
dangerous of these adverse effects is neuroexcitation.
Myoclonus and seizures have been reported with high
doses of morphine (3,4), hydromorphone (4,5), me-
peridine (6), fentanyl (7), diamorphine (8), and after
oral (9), IV (3,4,7), epidural (5), or intrathecal (8,10)
administration. Indeed, the recognized neuroexcitatory
effects of high-dose short-acting opioids, such as fenta-
nyl, alfentanil, and remifentanil, are routinely harnessed
to induce controlled electroencephalographic seizures
during epilepsy surgery at our institution (11,12).
The mechanism, and thus treatment, of opioid-
related neuroexcitation remains unclear. Previous
animal investigations have suggested that the procon-
vulsant action of morphine is mediated through the
3-glucuronide morphine metabolite (13) or nitric oxide
produced by constitutive nonspecific nitric oxide syn-
thase (14). Other studies have proposed that multiple
receptor systems are involved in triggering opioid-
induced seizures, including opioid, adrenergic, and
glutamatergic receptors (15,16), or by opioid antago-
nism of inhibitory -aminobutyric acid (GABA)ergic
neurotransmission (17). Finally, some animal reports
have implicated muscarinic and cannabinoid recep-
tors in morphine enhancement of seizures (18,19).
A neuroexcitatory mechanism involving direct ac-
tivation of opioid receptors has yet to be demonstrated
definitively in the intact hippocampus. The intact in
vitro hippocampal model allows precise control of the
tissue environment and the direct application of selec-
tive receptor ligands without the involvement of dif-
ferent pharmacokinetic factors that can influence the
access of such molecules to their respective site of
action. Furthermore, the intact hippocampus main-
tains the neural pathways directly involved in seizure
initiation and propagation, as well as the physiologic
neuronal rhythms (20). The present study aimed to
determine whether the neuroexcitatory effect of
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morphine is mediated through direct stimulation of
specific opioid receptors. We hypothesize that mor-
phine enhancement of seizure activity is mediated
through selective stimulation of opioid receptors in
the intact hippocampus.
METHODS
Dissection
The University Health Network Animal Care Com-
mittee review board approved this animal study pro-
tocol. C57/BL mice at 8th to 25th postnatal day were
anesthetized with halothane and decapitated in accor-
dance with the Canadian Animal Care Guidelines. The
brain was carefully removed and bathed in ice-cold
2–5°C oxygenated (95% O2, 5% CO2) standard artifi-
cial cerebrospinal fluid (ACSF) containing the follow-
ing: 123 mM NaCl, 2.5 mM KCl, 1.5 mM CaCl2, 2 mM
MgSO4, 25 mM NaHCO3, 1.2 mM NaH2PO4, and 15
mM glucose. After removal of the cerebellum and the
separation of the hemispheres at the midsagittal line,
spatulas were used to carefully remove the brainstem
and the midbrain region. The hippocampus was then
resected by gently sliding the spatula ventral to the
corpus callosum, making the first insertion at the
septal hippocampal region. The septum was left intact
and served as an anatomical marker for the location of
the septal and temporal hippocampus regions (Fig.
1A). Hippocampi were bathed in oxygenated ACSF at
room temperature for a minimum of 1.5 h before
subsequent transfer into the recording chamber (21).
Recording Chamber Environment
The intact hippocampus was maintained in a re-
cording chamber at a temperature of 34°C  0.5°C,
continuously perfused with oxygenated standard
ACSF and secured by micropins. Humidified warmed
oxygen flowed over the solution in the recording
chamber to decrease the evaporation of oxygen from
the perfusate. Solutions entered the chamber at a flow
rate of 5 mL/min, refilling the volume of the 0.6 mL
chamber with fresh solution eight times per minute.
Seizure-like electrographic activity was induced by
perfusing the tissue with low-Mg2 ACSF containing
the following: 123 mM NaCl, 5 mM KCl, 1.5 mM
CaCl2, 0.25 mM MgSO4, 25 mM NaHCO3, 1.2 mM
NaH2PO4, and 15 mM glucose.
Electrophysiology
Recordings were performed from the CA1 pyrami-
dal neuronal layer of the hippocampus by positioning
the hippocampus DG-CA3 region dependent on nylon
mesh and the CA1 region faced upwards. A Grass S44
(Grass Medical Instruments, West Warwick, RI)
stimulator with bipolar electrode was used to stimu-
late Schaffer collaterals (1–15 V, 0.1 ms) and extracel-
lular glass electrodes containing 150mMNaCl that were
positioned at locations yielding maximal evoked and
spontaneous field potential amplitudes in the CA1 stra-
tum pyramidale. Input/output relations were recorded
with stimulating pulses of 10 different intensities, evok-
ing subthreshold to suprathreshold population re-
sponses. All single-site recordings of seizure-like events
were obtained from themiddle of the hippocampus (Fig.
1A), and filtered with 1 kHz low-pass filter unless
otherwise stated, amplified, and recorded at 2 kHz
sampling rate with an Axopatch 200B amplifier (Axon
Instruments, Foster City, CA). The signals were digitized
using the 16-bit data acquisition system Digidata 1322A
(Axon Instruments, Foster City, CA). Data visual-
ization was achieved with Clampfit 8.2 (Axon In-
struments, Foster City, CA). All results are shown as
mean values  sem.
Figure 1. Seizure-like events recorded in the intact hippocampus during perfusion with low Mg2 artificial cerebrospinal fluid
(ACSF). (A) A diagram illustrating the intact whole mouse hippocampus that was maintained in vitro. The septal and
temporal poles are noted. The position of the recording electrode (F) is shown which corresponds to the location of the CA1
pyramidal cell layer of the hippocampus. (B) Electrophysiologic recordings showing spontaneous seizure-like events in the
intact hippocampus induced by lowMg2 ACSF perfusion. An expanded time scale of a single seizure-like event (box) shows
three distinct components. First component is a transition period with low frequency spikes followed by an early and late
seizure phases. (C) Further expansion of the time scale shows different components of the early and late seizure-like events.
The late seizure component consists of slow late burst and fast intraburst frequencies.
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Drugs
All drugs used in the present study were obtained
from Sigma-Aldrich (St. Louis, MO), except morphine
sulfate purchased from Abbott (Toronto, Canada).
Drugs were dissolved in standard ACSF or low Mg2
ACSF to designated concentrations as follows: mor-
phine (10, 30, and 100 M); selective -opioid receptor
agonist, DAMGO (10 M) and antagonist, B-FNA (10
M); -opioid receptor agonist, Dyn-A (10 M) and
antagonist, nor-BNI (10 M); and -opioid receptor
agonist, DPDPE (10 M) and antagonist, NTI (10 M).
Statistical Analysis
The electrographic seizure activity was quantified
by determining mean  sem of seizure duration, late
seizure frequency, and intraburst frequency (Figs. 1B
and C). The seizure duration is the time elapsed
between the start of the early phase and the termina-
tion of the late phase not including the transition, i.e.,
prodromal phase (Fig. 1B). Where applicable, data
were analyzed using one-way and repeated measures
ANOVA and paired and unpaired t-test. Statistical
significance was considered at a P  0.05.
RESULTS
Morphine Actions
Control experiments were performed to determine
the consistency and stability of the seizure activity
induced by perfusing the intact hippocampus with
low Mg2 ACSF. In each of 10 different hippocampi,
the recurrent seizure patterns were consistent and did
not change their electromorphologic appearance. Re-
current seizures had a mean duration of 87  5 s, and
there were 2  0.65 seizures per 10 min. Usually, the
recurrent seizure events started approximately 6–12 min
after the administration of low Mg2 ACSF and lasted
for approximately 95–120 min in a consistent and stable
manner. Single maximal postsynaptic population spikes
were evoked by stimulating the Schaefer collateral to
monitor the viability of the hippocampi. Experiments
were terminated if there was a deterioration of the
population spike amplitude below 75% relative to
their initial values. A single seizure consisted of an
early and a late phase (Fig. 1B). The early phase
consisted of a series of single spikes with a mean
frequency of 1 Hz. The late phase comprised of
multiple bursts with a mean burst frequency of 1.3 Hz.
Figure 2. Morphine actions on seizure-like events in the intact hippocampus in vitro. Morphine in a low concentration 10 M
depressed seizure-like events in the intact hippocampus in vitro (A) whereas a higher concentration 100 M enhanced seizure
activity (B). The effects of morphine 100 M were blocked by the concomitant application of naloxone 5 M (C).
Table 1. Naloxone Actions on Spontaneous Electrographic Seizure Activity Recorded from the Whole Hippocampus In Vitro
Naloxone 5 M (n  5) Naloxone 10 M (n  5)
Control Effect Recovery Control Effect Recovery
Seizure duration (s) 98.78 9.7 102 10.23 105.1 8.86 118.1 8.36 73.56* 3.46 94.61 7.67
Late burst frequency (Hz) 1.1 0.15 1.2 0.17 1.03 0.09 1.1 0.15 1.2 0.17 1.03 0.09
Intraburst frequency (Hz) 23.1 2.14 24 3.2 22.2 2.45 13.1 0.45 0.00 11.1 0.45
* Statistical significance from control (P  0.05).
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The intraburst frequency was defined as the number
of spikes per second contained in a single burst
occurring during the late phase of a seizure (Fig. 1C).
Because naloxone is considered a nonspecific opiate
antagonist for morphine, we performed experiments
to elucidate the action of this drug on the seizure
activity of the epilepsy model used in this study.
Naloxone 5 M applied to hippocampi perfused with
low Mg2 ACSF had no effect on the spontaneous
electrographic seizures. However, naloxone 10 M
had a statistically significant effect in attenuating
seizure duration (Table 1).
The application of morphine to intact hippocampi
exhibiting seizure activity revealed a biphasic effect.
Morphine 10 Mdecreased the duration of the seizure
activity and the number of recurrent seizure events
per 10 min (Figs. 2A and 3A). However, the late burst
and intraburst frequencies were not affected (Figs. 3B
and C). These effects were completely reversed after a
washout period of about 20 min. The addition of
naloxone 5 M to the perfusate did not reverse such
inhibitory actions of morphine. When higher concen-
trations of morphine (30 and 100 M) were applied,
seizure activity was enhanced in duration in a dose-
dependent manner (Figs. 2B and 3A). Naloxone 5 M
blocked such enhancement in seizure activity (Figs. 2C
and 3A). Meanwhile, higher morphine concentrations
did not significantly change the early phase frequency
but depressed the late bursting and intraburst
frequencies (Figs. 3B and C). Higher morphine con-
centrations (30 and 100 M) administered to the
hippocampi perfused with standard ACSF did not
cause any seizure activity. Moreover, the enhance-
ment of seizure activity in hippocampi perfused with
low Mg2 ACSF containing morphine was not sus-
tained when the same hippocampi were subsequently
perfused with standard ACSF containing morphine.
Effects of Selective Opioid Ligands
To address the question of which opioid receptor
was responsible for mediating the proseizure action of
morphine, we applied selective opioid agonists and
antagonists to hippocampi exhibiting seizure activity
when perfused with low Mg2 ACSF (Fig. 4; Table 2).
The  and  opiate receptor selective agonists,
DAMGO 10 M and Dyn-A 10 M, respectively,
enhanced seizure activity as evidenced by the increase
in seizure duration and number of recurrent seizure
events per 10-min intervals. Similar to the higher
morphine concentrations (30 and 100 M), the  and 
opiate receptor agonists decreased the late burst and
intraburst frequencies. On the contrary, the  and 
receptor antagonists, i.e., B-FNA and nor-BNI, respec-
tively, depressed seizure discharges in seizing
hippocampi perfused with low Mg2 ACSF. Such
depression of seizure discharges was in the form of a
decrease in seizure duration and the conversion of the
seizure into a state of stable firing rate (Figs. 4A and
B). The latter effect might have been due to the
agonist-induced shift of the neuronal activities from a
disinhibited “down-state” that leads to the seizures to
an active “up-state,” i.e., a stable increased firing rate.
Neither selective  receptor agonist DPDPE 10 M nor
its antagonist NTI 10 M had any significant effect on
the electrographic seizure events.
DISCUSSION
The most important finding of the present study is
that the neuroexcitatory action of morphine is medi-
ated through selective stimulation of the  and 
opiate receptor subtypes. This study is the first to
demonstrate that a high concentration of morphine
can enhance spontaneous seizure activity in an
apparent dose-dependent manner in the intact hip-
pocampus maintained in vitro. Such action had been
Figure 3. Dose-dependent effects of morphine on hippocam-
pus seizure-like events. Morphine 10 M decreased and
morphine 30 and 100 M increased the durations of seizure-
like events recorded from the intact hippocampus in a
dose-dependent manner (A). Morphine 30 and 100 M
suppressed the late burst and intraburst frequency compo-
nents of the seizure-like events (B and C). Naloxone 5 M
reversed the effects of morphine 30 and 100 M on the
duration but not on the late burst and intraburst frequencies
(A–C). Error bars represent (sem). Each morphine concen-
tration was applied to at least six intact hippocampi. *Sta-
tistical significance from control (P  0.05).
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demonstrated in whole-animal epilepsy models when
morphine at higher doses was administered intraperi-
toneally, IV, or intracerebroventicularly (22,23). This
study also confirms that morphine has a biphasic
effect, as reported in previous whole-animal studies
(23,24); that is, a low morphine concentration demon-
strated an antiseizure effect whereas higher morphine
concentrations enhanced spontaneous seizure activity.
The present investigations used an in vitro low Mg2
model of hippocampal epilepsy so as to examine the
possible mechanisms of morphine-induced seizures.
Low Mg2 leads to neuronal hyperexcitability that is
conductive for seizure generation by decreasing
membrane surface charge screening, decreasing Mg2
sensitive Ca2 channel block and decreasing the Mg2
blockade of N-methyl-d-aspartate receptors. This
Figure 4. Actions of selective opioid receptor agonists and antagonists on hippocampal seizure-like events.  (A) and  (B)
selective opioid receptor agonists and antagonists enhanced and suppressed spontaneous seizure-like events in the intact
hippocampus, respectively. On the contrary,  receptor agonists and antagonists (C) did not have any effect on hippocampus
seizure activity.
Table 2. Effects of Opiate Receptor Ligandsa on Spontaneous Electrographic Seizures Recorded from the Intact Hippocampus
In Vitro
-Receptor -Receptor -Receptor
Agonist
(DAMGO)
Antagonist
(B-FNA)
Agonist
(Dyn-A)
Antagonist
(Nor BNI)
Agonist
(DPDPE)
Antagonist
(NTI)
Seizure duration
(% control)b
129.59* 13.8 84.18* 10.1 137.487* 15.12 68.74* 6.87 82.03 10.66 109.91 12.64
Late burst frequency
(% control)b
57.26* 7.9 113.13 14.8 91.16* 13.6 89.01 9.97 92.68 12.98 103.68 16.59
Intraburst frequency
(% control)b
68.10* 1.36 92.62 3.34 61.46* 2.46 128.10 48 103.74 3.32 105.49 5.27
a Each ligand was applied to at least 6 intact hippocampi that developed seizure like-events when perfused with low Mg2 artificial cerebrospinal fluid.
b % Control  measurement during ligand application/control measurement  100.
* Statistical significance from control (P  0.05).
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implies that different strategies can be used to treat
opioid-induced enhancement of seizure activities. It is
true that high concentrations of morphine did not
elicit seizure activities in the present study when the
Mg2 concentrations were normal. However, our con-
clusions from the low Mg2 model can be relevant to
those instances when morphine induces seizure activi-
ties in the clinical situation (2–4). The lowMg2model
of epilepsy showed seizure-like discharges similar to
the progression of electroencephalographic abnor-
malities in patients with partial complex seizures and
partial status epilepticus (22). It is also well recognized
that a low serum Mg2 concentration can cause sei-
zures, and IV Mg2 administration can prevent and
control convulsions associated with eclampsia. Hence,
it is reasonable to assume that the findings and
conclusions of the present study can have relevance to
various clinical situations.
The antiseizure effect of morphine observed in this
study was similar to previously reported findings in
whole-animal models of epilepsy (23,24). The mecha-
nism of this effect in our model is probably not related
to the direct stimulation of specific opioid receptors
because adding naloxone 5 M to the perfusate with
morphine 10 M did not reverse the antiseizure effect.
It is possible that the mechanism of such action is
mediated through inhibitory effects on glutamatergic
excitatory pathways and increasing GABAergic activ-
ity. Although the antiseizure effect might be clinically
insignificant, its occurrence indicates that our intact
isolated hippocampal epilepsy model is sensitive
enough to experimentally simulate the biphasic neu-
roexcitatory actions of morphine. The clinical implica-
tions of this effect can be expressed in a historical
context, as opioids in the past had been used to abort
intractable seizures in epilepsy patients (25).
Morphine-enhanced seizure activity was depicted
by an apparent dose-dependent increase in the dura-
tion of ictal events. However, we also observed a
simultaneous decrement in the ictal late burst and
intraburst frequencies. Late burst and intraburst fre-
quencies reflect hypersynchronous behavior of the
neuronal networks involved in initiating and main-
taining seizure activity (26). The morphine-induced
depression of both the late burst and intraburst fre-
quencies of the seizure-like events were probably due
to multiple morphine effects at the cellular level that
should be further investigated to identify their patho-
physiologic significance.
Our results validate the hypothesis that the prosei-
zure effect of morphine is mediated through selective
 and  opioid receptor stimulation, but not activation
of  receptor subtypes. This is because spontaneous
seizure activity was enhanced by specific  and 
agonists, i.e., DAMGO and Dyn-A, respectively, and
suppressed by  and  antagonists, i.e., B-FNA and
nor-BNI, respectively. We can only speculate on the
“downstream” mechanisms by which  and -opioid
receptor stimulation enhances spontaneous seizure
activity. Stimulation of the  and -receptor subtypes
can lead to a state of disinhibition in CA1 pyramidal
neurons similar to that described in a subpopulation
of periaqueductal gray neuronal elements (27). The
disinhibitory effect may be mediated by decreasing
the recurrent inhibition of the CA1 pyramidal cells
through suppression of inhibitory GABAergic inter-
neurons (28). The latter leads to enhancement of the
recorded seizure-like events in the intact hippocam-
pus. Suppression of GABAergic interneurons may be
produced by presynaptic mechanisms that decrease
GABA release. Accordingly, Vaughan et al. (27) re-
ported that selective  and -receptor agonists can
reduce the amplitudes of evoked inhibitory postsyn-
aptic currents with a simultaneous decrement in the
rate of spontaneous miniature inhibitory postsynaptic
currents without any effect on their amplitude distri-
butions or kinetics in mice with intact opioid receptor
subtypes. Another possibility is that the suppression
of GABAergic interneurons can be a consequence of
activating an inward rectifying K current. This cur-
rent was found to be enhanced by  and  agonists
(27).
In conclusion, our findings indicate that the prosei-
zure effect of morphine is mediated through selective
stimulation of  and  opiate receptors. The observed
dose-dependent mechanism of morphine neuroexcita-
tion underscores the importance of careful adjustment
and individualized opioid dosing in the clinical set-
ting, and could help guide the development of thera-
peutic strategies to prevent and treat opioid-related
seizures.
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